15 November 2022 - On 27 October 2022, the TGA provisionally approved the Pfizer (Comirnaty) Bivalent Original/Omicron BA.1 vaccine (subsequently referred to as Pfizer bivalent) for use as a booster COVID-19 vaccine in people aged 18 years and older.
The Australian Technical Advisory Group on Immunisation has evaluated the immunogenicity, efficacy, and safety data on this vaccine.